Pfizer wins U.S. approval for new HIV drug

	Tweet

Pfizer Inc said on Monday that U.S. regulators approved its AIDS drug Selzentry, the first in a new class of oral HIV medicines.

Selzentry is the first drug designed to keep the HIV virus that causes AIDS from entering healthy immune cells. Older AIDS medicines attack the virus itself. 

The drug, also known as maraviroc, blocks the CCR5 co-receptor that serves as a main doorway for the HIV virus into immune cells.

The U.S. Food and Drug Administration approved Selzentry for use in patients who have tried other medicines and for those for whom a diagnostic test has confirmed their HIV strain is linked to the CCR5 receptor.

The world’s largest drugmaker said it expects the drug to be available next month.

Pfizer said in June that the FDA would approve the drug once certain conditions had been met.

The New York-based company is counting on new medicines like Selzentry to help drive profits as several blockbuster medicines lose patent protection and its top-selling Lipitor cholesterol treatment faces strong competition.

Industry analysts have projected annual Selzentry sales of about $500 million by 2011. 

RELATED STORIES:
FDA Advisory Panel Approves Home HIV Test Kit   FDA Approves New In-Home HIV Test   Home HIV test advances   Survey Reveals Support for Over-the Counter HIV Testing   F.D.A. Panel Weighs Preventive Use of H.I.V. Drug   Stem Cell Therapy Shows Promise in Fight Against HIV   Progress against HIV thwarted by patients’ unmet needs   California to test pill for HIV prevention   Mechanism of HIV spread has potential for future drug therapy   Seeking HIV treatment clues in the neem tree   HIV Prevention Pill’s Value Varies by Target   Using AIDS drugs to prevent infection: a bargain?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]